Raising population of the world has triggered many diseases that can’t be controlled easily; lot of unhealthy living lifestyles has also grown. Rising sugar in blood may cause serious health problems in the patients suffering from diabetes and its acute complications for to cope with this issues there are many human insulin drugs and delivery devices that are available in the market. Human insulin drugs and delivery devices are mainly used for injecting the insulin in the human body. Factors like obesity and overweight are highly responsible for the incidences of diabetics and other diseases. Raising sugar patient population affects the growth in Insulin market. Same time manufacturing cost of insulin drugs is biggest challenge in the market growth; also requirements are affecting the growth of said market.
How Big is The Global Human Insulin Drugs & Delivery Devices Market?
The Global Human Insulin Drugs & Delivery Devices Market is expected to be around US$ 68.80 Billion by 2028 at a CAGR of 8.00% in the given forecast period.
The major driving factors of Global Human Insulin Drugs & Delivery Devices Market As follows:
The restraining factors of Global Insulin Drugs & Delivery Devices Market as follows:
This report provides:
1) An overview of the global market for Insulin Drugs & Delivery Devices.
2) Analyses of global market trends, with data from 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2028.
3) Identifications of new market opportunities and targeted promotional plans for Global Insulin Drugs & Delivery Devices Market
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
Report scope:
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Eli Lilly and Company (U.S.), Biocon Ltd. (India), Julphar (U.A.E.), Sanofi (France), Ypsomed AG (Switzerland), Becton, Dickinson and Company (U.S.), Wockhardt Ltd. (India). Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.
The Global Human insulin Drugs & Delivery Market has been segmented as below:
By Product Analysis:
By Drug Analysis:
By Delivery Devices Analysis:
By Regional Analysis:
Reasons to Buy this Report:
1) Obtain the most up to date information available on all Global Human Insulin Drugs & Delivery Devices Market.
2) Identify growth segments and opportunities in the industry.
3) Facilitate decision making on the basis of strong historic and forecast of Global Human Insulin Drugs & Delivery Devices Market data.
4) Assess your competitor’s refining portfolio and its evolution.
Customization:
We can offer you custom research reports as per client’s special requirements.
Below are our New Reports :-
Ophthalmology Drugs & Devices Market
Orally Disintegrating Tablet (ODT) market
1 INTRODUCTION
1.1 Key Take Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
2 Research Methodology
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions
2.4.1 Assumptions
3 Executive Summary
3.1 Introduction
3.2 Current Market Scenario
3.3 Future Outlook
3.4 Conclusion
4 Premium Insights
4.1 Global Market (2019–2025)
4.2 Global Market Size, By Product (2019)
4.3 Global HI Drugs Market Size, By Product Type (2019-2025)
4.4 Global HI Drugs Market Size, By Brand (2019)
4.5 Global HI Delivery Devices Market Size, By Type (2019-2025)
4.6 Global Market Size, By Region (2019-2025)
5 Market Overview
5.1 Introduction
5.2 Market Segmentation
5.3 Market Evolution
5.4 Market Dynamics
5.4.1 Key Market Drivers
5.4.1.1 Growth in the Number of Diabetic Patients
5.4.1.2 Increasing Population Exposure to Key Risk Factors Leading to Diabetes
5.4.1.3 Rising Market Demand for HI Analogs
5.4.1.4 Technological Advancements in HI Delivery Devices
5.4.1.5 Favorable Medical Reimbursement Scenario in Developed Countries
5.4.2 Key Market Restraints
5.4.2.1 Stringent Regulatory Requirements for Product Approval
5.4.3 Key Market Opportunities
5.4.3.1 Emerging Markets
5.4.3.2 Expected Patent Expiry of Key HI Drugs
5.4.4 Key Market Challenge
5.4.4.1 High Product Manufacturing Costs
6 Industry Insights
6.1 Introduction
6.2 Industry Trends
6.2.1 Growing Market Demand for HI Pens
6.2.2 Increasing Market Focus on the Pipeline Development of Novel Human Insulin Therapies
6.3 Pipeline Analysis
6.3.1 By Company
6.3.2 By Clinical Trial Phase
6.3.3 Porter’s Five Force Analysis
6.3.3.1 Threat From New Entrants
6.3.3.2 Threat From Substitutes
6.3.3.3 Bargaining Power of Buyers
6.3.3.4 Bargaining Power of Suppliers
6.3.3.5 Intensity of Competitive Rivalry
7 Global Human Insulin Market, By Product Type
7.1 Introduction
7.2 HI Drugs
7.3 HI Delivery Devices
8 Global Human Insulin Drugs Market, By Type
8.1 Introduction
8.2 Insulin Analogs and Biosimilars
8.2.1 Long-Acting Biosimilars
8.2.2 Rapid-Acting Biosimilars
8.2.3 Premixed Biosimilars
8.3 HI Biologics
8.3.1 Short-Acting Biologics
8.3.2 Intermediate-Acting Biologics
8.3.3 Premixed Biologics
9 Global Human Insulin Drugs Market, By Brand
9.1 Introduction
9.2 HI Analogs and Biosimilars
9.2.1 Lantus
9.2.2 Novorapid and Novolog
9.2.3 Humalog
9.2.4 Other Brands
9.3 HI Biologics
9.3.1 Actrapid, Mixtard, and Insulatard
9.3.2 Humulin
9.3.3 Insuman
10 Global Human Insulin Market, By Delivery Devices
10.1 Introduction
10.2 Syringes
10.3 Pens
10.3.1 Disposable Pens
10.3.2 Reusable Pens
10.4 Pen Needles
10.4.1 Standard Pen Needles
10.4.2 Safety Pen Needles
11 Global Human Insulin Market, By Application
11.1 Introduction
11.2 Type I Diabetes
11.3 Type II Diabetes
12 Human Insulin Market, By Region
12.1 Introduction
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 France
12.3.3 U.K.
12.3.4 Rest of Europe (RoE)
12.4 Asia-Pacific (APAC)
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Rest of Asia-Pacific (RoAPAC)
12.5 Rest of the World (RoW)
13 Competitive Landscape
13.1 Overview
13.2 Market Share Analysis
13.2.1 HI Drugs Market
13.2.2 HI Delivery Devices Market
13.3 Competitive Scenario
13.4 Recent Developments
13.4.1 Geographical Expansions
13.4.2 Agreements, Collaborations, and Partnerships
13.4.3 New Product Launches
13.4.4 Awareness Programs
13.4.5 Funding & Scholarships
13.4.6 Strategic Acquisitions
14 Company Profiles
14.1 Introduction
14.1.1 Geographic Benchmarking
14.1.2 Strategic Benchmarking
14.1.2.1 Capacity Building
14.1.2.2 Product Development and Commercialization
14.2 B. Braun Melsungen AG
14.2.1 Business Overview
14.2.2 Product Portfolio
14.2.3 Recent Developments
14.3 Becton, Dickinson and Company
14.3.1 Business Overview
14.3.2 Product Portfolio
14.3.3 Recent Developments
14.4 Biocon Limited
14.4.1 Business Overview
14.4.2 Product Portfolio
14.5 Biodel Inc.
14.5.1 Business Overview
14.5.2 Product Portfolio
14.5.3 Recent Developments
14.6 ELI Lilly and Company
14.6.1 Business Overview
14.6.2 Product Portfolio
14.6.3 Recent Developments
14.7 Julphar (Also Known as Gulf Pharmaceutical Industries)
14.7.1 Business Overview
14.7.2 Product Portfolio
14.8 NOVO Nordisk A/S
14.8.1 Business Overview
14.8.2 Product Portfolio
14.8.3 Recent Developments
14.9 Sanofi
14.9.1 Business Overview
14.9.2 Product Portfolio
14.9.3 Recent Developments
14.10 Wockhardt Limited
14.10.1 Business Overview
14.10.2 Product Portfolio
14.10.3 Recent Developments
14.11 Ypsomed AG
14.11.1 Business Overview
14.11.2 Product Portfolio
14.11.3 Recent Developments
The Global Human insulin Drugs & Delivery Market has been segmented as below:
By Product Analysis:
By Drug Analysis:
By Delivery Devices Analysis:
By Regional Analysis:
SUBSCRIBE TO OUR NEWSLETTERS
